CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of $1.34 per share for the year. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share.
CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The business had revenue of $0.46 million during the quarter, compared to analysts' expectations of $0.11 million.
Other equities analysts have also issued reports about the company. Morgan Stanley reissued an "overweight" rating and set a $55.00 price target on shares of CG Oncology in a research report on Friday, March 7th. TD Cowen began coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating on the stock. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $63.88.
Check Out Our Latest Analysis on CG Oncology
CG Oncology Price Performance
NASDAQ CGON traded down $1.54 during trading hours on Wednesday, hitting $17.20. The company had a trading volume of 2,148,002 shares, compared to its average volume of 679,538. CG Oncology has a fifty-two week low of $16.64 and a fifty-two week high of $46.99. The firm's 50 day moving average is $26.99 and its 200 day moving average is $31.30. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -12.11 and a beta of 1.24.
Hedge Funds Weigh In On CG Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of CGON. Wellington Management Group LLP grew its stake in CG Oncology by 274.4% during the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock worth $54,792,000 after buying an additional 1,400,251 shares during the last quarter. California State Teachers Retirement System lifted its position in CG Oncology by 115.3% in the 4th quarter. California State Teachers Retirement System now owns 38,768 shares of the company's stock valued at $1,112,000 after purchasing an additional 20,763 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in CG Oncology during the 4th quarter valued at about $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of CG Oncology by 496.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,902 shares of the company's stock valued at $3,611,000 after purchasing an additional 104,780 shares during the period. Finally, Woodline Partners LP raised its holdings in shares of CG Oncology by 3.8% during the fourth quarter. Woodline Partners LP now owns 628,885 shares of the company's stock valued at $18,036,000 after buying an additional 22,987 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
CG Oncology Company Profile
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Recommended Stories
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
